Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2014 1
2015 1
2017 1
2018 3
2019 1
2020 2
2021 1
2022 2
2023 4
2024 5
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Citations

3 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Low-dose naltrexone as a treatment for chronic fatigue syndrome.
Bolton MJ, Chapman BP, Van Marwijk H. Bolton MJ, et al. BMJ Case Rep. 2020 Jan 6;13(1):e232502. doi: 10.1136/bcr-2019-232502. BMJ Case Rep. 2020. PMID: 31911410 Free PMC article.
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. ...Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people …
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countr …
Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone.
Löhn M, Wirth KJ. Löhn M, et al. J Transl Med. 2024 Jul 5;22(1):630. doi: 10.1186/s12967-024-05412-3. J Transl Med. 2024. PMID: 38970055 Free PMC article. Review.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease with a broad overlap of symptomatology with Post-COVID Syndrome (PCS). ...TRPM3 dysfunction in NK cells can be improved by naltrexone in vitro and ex vivo, which may explain …
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease with a broad overlap of symptomatology w …
Low-dose Naltrexone Improves post-COVID-19 condition Symptoms.
Tamariz L, Bast E, Klimas N, Palacio A. Tamariz L, et al. Clin Ther. 2024 Mar;46(3):e101-e106. doi: 10.1016/j.clinthera.2023.12.009. Epub 2024 Jan 23. Clin Ther. 2024. PMID: 38267326
The relative hazard of improvement for those taking low-dose naltrexone was 5.04 (95% CI, 1.22-20.77; P = 0.02) compared with physical therapy alone. Both fatigue and pain were improved in patients taking low-dose naltrexone; only …
The relative hazard of improvement for those taking low-dose naltrexone was 5.04 (95% CI, 1.22-20.77; P = 0.02) compare …
Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia.
Naik H, Cooke E, Boulter T, Dyer R, Bone JN, Tsai M, Cristobal J, McKay RJ, Song X, Nacul L. Naik H, et al. BMJ Open. 2024 May 13;14(5):e085272. doi: 10.1136/bmjopen-2024-085272. BMJ Open. 2024. PMID: 38740499 Free PMC article.
INTRODUCTION: A significant proportion of individuals suffering from post COVID-19 condition (PCC, also known as long COVID) can present with persistent, disabling fatigue similar to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-viral …
INTRODUCTION: A significant proportion of individuals suffering from post COVID-19 condition (PCC, also known as long COVID) can present wit …
Pilot Study of Low-dose Naltrexone for the Treatment of Chronic Pain Due to Arthritis: A Randomized, Double-blind, Placebo-controlled, Crossover Clinical Trial.
Beaudette-Zlatanova B, Lew RA, Otis JD, Branch-Elliman W, Bacorro E, Dubreuil M, Eyvazzadeh C, Kaur M, Lazzari AA, Libbey C, Monach PA. Beaudette-Zlatanova B, et al. Clin Ther. 2023 May;45(5):468-477. doi: 10.1016/j.clinthera.2023.03.013. Epub 2023 Apr 10. Clin Ther. 2023. PMID: 37045708 Clinical Trial.
PURPOSE: Low-dose naltrexone (LDN) is commonly used to control pain and other symptoms, especially in patients with autoimmune diseases, but with limited evidence. This study tests the efficacy of LDN in reducing chronic pain in patients with osteoarth …
PURPOSE: Low-dose naltrexone (LDN) is commonly used to control pain and other symptoms, especially in patients with aut …
Real-World Effectiveness and Tolerability of Low Dose Naltrexone to Treat Chronic Pain: A Retrospective Cohort Study of One Pain Physician's Practice.
Aalto H, Paul S, McEwen V. Aalto H, et al. J Pain Res. 2025 Dec 10;18:6637-6649. doi: 10.2147/JPR.S561662. eCollection 2025. J Pain Res. 2025. PMID: 41399763 Free PMC article.
PURPOSE: Low-dose naltrexone (LDN) is an off-label treatment for chronic pain, with evidence supporting its use mainly consisting of small-scale studies. ...Adverse effects occurred in 49.5% of patients, most frequently nausea and fatigue. No se …
PURPOSE: Low-dose naltrexone (LDN) is an off-label treatment for chronic pain, with evidence supporting its use …
Low-Dose Naltrexone Use in Postural Orthostatic Tachycardia Syndrome: A Case Series.
Stallkamp Tidd SJ, Cantrell C, Greene BD, Wilson R. Stallkamp Tidd SJ, et al. Cureus. 2023 Aug 13;15(8):e43426. doi: 10.7759/cureus.43426. eCollection 2023 Aug. Cureus. 2023. PMID: 37706146 Free PMC article.
Introduction In recent years, low-dose naltrexone has emerged as a novel off-label therapy for many chronic conditions including postural orthostatic tachycardia syndrome (POTS), however, there is little evidence for its efficacy. Methods In this insti …
Introduction In recent years, low-dose naltrexone has emerged as a novel off-label therapy for many chronic cond …
Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.
Cabanas H, Muraki K, Eaton-Fitch N, Staines DR, Marshall-Gradisnik S. Cabanas H, et al. Front Immunol. 2021 Jul 13;12:687806. doi: 10.3389/fimmu.2021.687806. eCollection 2021. Front Immunol. 2021. PMID: 34326841 Free PMC article.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating multi-systemic chronic condition of unknown aetiology classified as an immune dysfunction syndrome and neurological disorder. ...Based on the benefits reported by patients on their …
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating multi-systemic chronic condition of unkno …
Low-Dose Naltrexone for Severe Fibromyalgia Syndrome: A Report of a Case With Two-Year Follow-Up.
Moser U. Moser U. Cureus. 2025 May 10;17(5):e83824. doi: 10.7759/cureus.83824. eCollection 2025 May. Cureus. 2025. PMID: 40491623 Free PMC article.
Effective treatment options are therefore needed to supplement conventional therapies. Naltrexone is used in many countries as an off-label therapy in low doses for several chronic immunomodulatory disorders, including FMS. ...Instead, low-dose …
Effective treatment options are therefore needed to supplement conventional therapies. Naltrexone is used in many countries as an off …
Low Dose Naltrexone in the Treatment of Fibromyalgia.
Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Metyas S, et al. Curr Rheumatol Rev. 2018;14(2):177-180. doi: 10.2174/1573397113666170321120329. Curr Rheumatol Rev. 2018. PMID: 28325149 Clinical Trial.
It is hypothesized that low dose naltrexone causes transient blockade of opioid receptors centrally resulting in a rebound of endorphin function which may attenuate pain in fibromyalgia. RESULTS: Two small prospective pilot studies have previously shown that …
It is hypothesized that low dose naltrexone causes transient blockade of opioid receptors centrally resulting in a rebo …
27 results